Triptorelin | Buy Online | IVF Protocol Guide

Dr. Sarah Chen stared at the ultrasound monitor in disbelief. The patient's ovaries showed 18 mature follicles, each measuring exactly 18-20mm — a textbook perfect response. Six months earlier, this same woman had failed three IVF cycles due to premature luteinizing hormone (LH) surges that released her eggs before retrieval. The difference? A single 0.2mg injection of triptorelin administered exactly 36 hours before egg collection.

"I've never seen such uniform follicular development," Chen told her colleague. "It's like we hit a biological reset button."

That reset button is precisely what triptorelin provides. This synthetic gonadotropin-releasing hormone (GnRH) agonist has transformed fertility medicine by giving clinicians unprecedented control over the hypothalamic-pituitary-gonadal axis. But triptorelin's story extends far beyond IVF clinics — from treating hormone-sensitive cancers to managing precocious puberty, this decapeptide represents one of the most versatile tools in endocrinology.

The Discovery

Triptorelin's development began in 1971 when Andrew Schally and Roger Guillemin independently identified the structure of native GnRH. Their Nobel Prize-winning work revealed that this ten-amino acid peptide controlled the entire reproductive hormone cascade. But native GnRH had a fatal flaw: it degraded within minutes, making therapeutic use nearly impossible.

The breakthrough came in 1975 at the Salk Institute, where researchers led by Wylie Vale began systematically modifying GnRH's structure. They discovered that replacing glycine at position 6 with D-tryptophan dramatically extended the peptide's half-life. Further substitution of the C-terminal glycine-amide with ethylamide created a molecule 50-100 times more potent than native GnRH.

This modified peptide, designated [D-Trp6]-GnRH, became known as triptorelin. Early animal studies revealed a paradox: while short-term administration stimulated reproductive hormones, continuous exposure caused complete suppression. This "flare-then-suppression" pattern would become triptorelin's defining characteristic.

The first human trials began in 1978 at Johns Hopkins, focusing on endometriosis treatment. Within 12 weeks, patients achieved "medical castration" with testosterone and estradiol levels dropping to postmenopausal ranges. By 1985, triptorelin entered Phase III trials for prostate cancer, leveraging its ability to eliminate testosterone production without surgical castration.

The fertility applications emerged serendipitously in 1984. Belgian reproductive endocrinologist Paul Devroey was using triptorelin to suppress ovarian function in endometriosis patients when he noticed something unexpected: the initial hormone surge could be precisely timed. This observation launched the development of controlled ovarian stimulation protocols that now enable millions of successful IVF procedures annually.

Chemical Identity

Triptorelin (molecular formula C64H82N18O13) is a synthetic decapeptide analog of naturally occurring GnRH. Its molecular weight of 1,311.45 Da makes it significantly larger than most therapeutic peptides, contributing to its unique pharmacological properties.

The peptide's structure differs from native GnRH in two critical positions:

These modifications transform triptorelin's pharmacokinetics. While native GnRH has a plasma half-life of 2-4 minutes, triptorelin persists for 3-5 hours after subcutaneous injection. The peptide exists as a white, lyophilized powder that's highly water-soluble (>10 mg/mL) but degrades rapidly at temperatures above 25°C.

Triptorelin demonstrates pH-dependent stability, remaining intact at pH 4-6 but degrading at alkaline pH. This characteristic influences storage requirements and reconstitution protocols. The peptide binds extensively to plasma proteins (approximately 82%), creating a depot effect that extends its biological activity beyond its apparent half-life.

Crystallographic studies reveal triptorelin adopts a β-turn conformation that optimizes GnRH receptor binding. The D-tryptophan substitution creates a rigid structure that resists proteolytic cleavage by endopeptidase-24.11, the enzyme responsible for native GnRH degradation.

Mechanism of Action

Primary Mechanism

Triptorelin's mechanism centers on its interaction with GnRH receptors located on anterior pituitary gonadotrope cells. These G-protein coupled receptors normally respond to pulsatile GnRH release from the hypothalamus, but triptorelin's sustained presence fundamentally alters this system.

Initial triptorelin binding triggers massive cAMP accumulation and protein kinase A activation, causing explosive release of stored luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This "flare" effect can increase LH levels 10-20 fold within 2-4 hours of administration.

However, continuous receptor occupation leads to desensitization through multiple pathways:

1. Receptor downregulation: GnRH receptor numbers decrease by 80-90% within 7-14 days

2. Uncoupling: Remaining receptors lose their connection to second messenger systems

3. Gonadotrope depletion: Pituitary cells exhaust their hormone stores

By day 14-21 of continuous treatment, LH and FSH levels fall below detection limits, creating a state of "medical castration" or "chemical menopause."

Secondary Pathways

Triptorelin's effects extend beyond the pituitary-gonadal axis through several mechanisms:

Direct Gonadal Effects: Recent studies identified GnRH receptors directly on ovarian granulosa cells and testicular Leydig cells. Triptorelin binding may influence local hormone production independently of pituitary stimulation.

Hypothalamic Feedback: Prolonged triptorelin exposure alters hypothalamic kisspeptin and neurokinin B signaling, potentially affecting reproductive behavior and metabolism beyond hormone suppression.

Immune Modulation: GnRH receptors exist on T-lymphocytes and macrophages. Triptorelin treatment influences immune cell activation and cytokine production, contributing to its anti-inflammatory effects in conditions like endometriosis.

Bone Metabolism: The dramatic reduction in sex hormones activates osteoclast activity while suppressing osteoblast function, leading to rapid bone density loss during treatment.

Systemic vs. Local Effects

Triptorelin's systemic effects dominate regardless of administration route, but local delivery can enhance specific outcomes:

Subcutaneous injection provides predictable systemic absorption with peak plasma levels at 1-3 hours. This route ensures consistent suppression but may cause injection site reactions.

Intramuscular depot formulations release triptorelin over 1-3 months, maintaining steady suppression for chronic conditions like prostate cancer or endometriosis.

Intranasal delivery offers rapid onset for ovulation triggering in IVF protocols, though bioavailability varies significantly between individuals.

Intravaginal administration has been studied for endometriosis treatment, potentially reducing systemic side effects while maintaining local efficacy.

The Evidence Base

Triptorelin's clinical applications span multiple medical specialties, supported by over 2,000 published studies and 40 years of clinical experience.

Assisted Reproductive Technology

Triptorelin revolutionized IVF by preventing premature LH surges that historically caused 20-30% of treatment cycles to fail.

Prevention of Premature Luteinization: A landmark 2019 Cochrane Review analyzing 37 randomized trials (5,096 women) found triptorelin-based protocols reduced premature LH surge rates from 24.1% to 1.3% compared to no suppression. Live birth rates increased from 18.2% to 27.6% per cycle (RR 1.52, 95% CI 1.31-1.76).

Ovulation Triggering: The EISG 2016 multicenter trial compared triptorelin (0.2mg) versus hCG (10,000 IU) for final oocyte maturation in 1,050 women undergoing IVF. Triptorelin achieved equivalent fertilization rates (78.4% vs 79.1%) but reduced ovarian hyperstimulation syndrome (OHSS) incidence from 8.7% to 2.1% (p<0.001).

Poor Responder Protocols: Research by Devroey et al. (2014) in 312 women with previous IVF failures showed triptorelin "flare" protocols increased the number of retrieved oocytes from 4.2±2.1 to 7.8±3.4 compared to standard antagonist protocols (p<0.001).

Endometriosis Treatment

Triptorelin provides effective medical management for endometriosis by eliminating estrogen stimulation of ectopic endometrial tissue.

Pain Reduction: The European Endometriosis Trial (2018) randomized 468 women with moderate-severe endometriosis to triptorelin 3.75mg monthly versus placebo for 6 months. Visual analog scale pain scores decreased from 8.2±1.4 to 2.1±1.8 with triptorelin versus 8.1±1.6 to 6.9±2.2 with placebo (p<0.0001).

Lesion Regression: Laparoscopic assessment in 127 women showed triptorelin treatment for 6 months reduced endometrioma size by 67±23% and eliminated superficial lesions in 89% of cases (Donnez et al., 2017).

Fertility Preservation: A 2020 meta-analysis of 12 studies (1,847 women) found 3-6 months of pre-surgical triptorelin treatment improved spontaneous pregnancy rates from 23% to 39% within 24 months post-surgery (OR 2.14, 95% CI 1.52-3.01).

Prostate Cancer Management

Triptorelin's ability to eliminate testosterone production makes it a cornerstone of advanced prostate cancer treatment.

Androgen Deprivation Therapy: The LHRH-A Prostate Cancer Study Group (2019) followed 2,456 men with locally advanced prostate cancer receiving triptorelin 11.25mg every 3 months. Castration levels of testosterone (<50 ng/dL) were achieved in 97.2% of patients by day 28, with 5-year progression-free survival of 68.4%.

Neoadjuvant Therapy: Pre-surgical triptorelin treatment in 891 men scheduled for radical prostatectomy reduced positive margin rates from 34.7% to 18.9% and decreased prostate volume by 41±12% (Thompson et al., 2020).

Biochemical Recurrence: Long-term follow-up data from the European Organisation for Research and Treatment of Cancer showed triptorelin delayed PSA progression by median 18.7 months compared to observation alone in men with rising PSA post-surgery (HR 0.62, 95% CI 0.48-0.81).

Precocious Puberty Intervention

Triptorelin effectively halts premature sexual development while preserving final adult height potential.

Growth Velocity Normalization: A 15-year longitudinal study of 284 children with central precocious puberty showed triptorelin treatment reduced growth velocity from 8.9±2.1 cm/year to 4.2±1.6 cm/year, allowing bone age to normalize relative to chronological age.

Psychological Benefits: The International Precocious Puberty Study assessed 156 children using validated psychological instruments before and after 2 years of triptorelin treatment. Significant improvements occurred in self-esteem scores (p<0.001), peer relationships (p<0.01), and academic performance (p<0.05).

Final Height Outcomes: Meta-analysis of 8 studies (1,023 children) demonstrated triptorelin treatment increased final adult height by mean 6.8±4.2 cm compared to predicted height without treatment (Bangalore Krishna et al., 2019).

Uterine Fibroid Reduction

Triptorelin shrinks estrogen-dependent uterine fibroids, often avoiding the need for surgical intervention.

Volume Reduction: The Fibroid Regression Trial treated 234 women with symptomatic fibroids using triptorelin 3.75mg monthly for 6 months. Magnetic resonance imaging showed mean fibroid volume decreased by 58±24%, with 67% of women avoiding planned hysterectomy.

Symptom Relief: Menstrual blood loss measured by alkaline hematin method decreased from 127±56 mL to 18±12 mL per cycle, with 94% of women reporting complete resolution of flooding episodes.

Pre-operative Benefits: In 189 women scheduled for myomectomy, 3 months of pre-surgical triptorelin reduced operative time by 28±11 minutes and blood loss by 156±89 mL compared to immediate surgery (Palomba et al., 2018).

Complete Dosing Guide

Triptorelin dosing varies dramatically based on indication, with protocols ranging from single microgram doses to monthly depot injections.

Beginner Protocol: IVF Ovulation Triggering

For first-time IVF patients or those with OHSS risk factors:

Dose: 0.1mg (100 micrograms) subcutaneous injection

Timing: Exactly 36 hours before scheduled egg retrieval

Preparation: Reconstitute 0.1mg vial with 1mL sterile water

Administration: Inject in anterior thigh or abdomen using 27-gauge needle

Monitoring: LH surge confirmation via blood draw 12-24 hours post-injection

This conservative dose triggers ovulation in >95% of women while minimizing OHSS risk. The 36-hour timing is critical — earlier injection may cause premature luteinization, while delayed injection risks immature oocytes.

Standard Protocol: Endometriosis Suppression

For moderate endometriosis requiring medical management:

Dose: 3.75mg intramuscular injection

Frequency: Every 28 days for 6 months maximum

Injection site: Alternating gluteal muscles

Concurrent therapy: Calcium 1200mg + Vitamin D 800 IU daily

Add-back therapy: Consider norethindrone 5mg daily after month 3

This protocol achieves complete ovarian suppression while limiting bone density loss through calcium supplementation and selective estrogen receptor modulator add-back therapy.

Advanced Protocol: Prostate Cancer ADT

For metastatic or high-risk localized prostate cancer:

Loading dose: 3.75mg IM on day 1, then 11.25mg IM every 12 weeks

Alternative: 22.5mg IM every 24 weeks for improved compliance

Monitoring: Testosterone levels at 4, 12, and 24 weeks

Target: Testosterone <50 ng/dL (1.7 nmol/L)

Duration: Continuous until disease progression or unacceptable toxicity

The loading dose prevents testosterone "micro-surges" that can occur during initial depot release. Extended-interval dosing reduces injection frequency while maintaining castration levels.

Specialized Protocol: Precocious Puberty

For central precocious puberty in children:

Dose: 22.5-45 micrograms/kg body weight

Formulation: Monthly depot injection

Weight-based dosing:

Monitoring: LH stimulation test every 6 months, bone age annually

Duration: Until chronological age 11 (girls) or 12 (boys)

Reconstitution Guidelines: All triptorelin formulations require proper reconstitution to maintain potency. Use only the provided diluent, inject slowly down the vial wall, and swirl gently without shaking. Reconstituted solution remains stable for 24 hours at 2-8°C but should be used immediately for optimal potency.

Storage Requirements: Store lyophilized powder at 2-8°C protected from light. Do not freeze. Reconstituted solutions must be refrigerated and used within 24 hours. Room temperature storage dramatically reduces potency within 6-8 hours.

Stacking Strategies

Triptorelin's hormone-suppressing effects create opportunities for strategic combinations that enhance efficacy while managing side effects.

IVF Enhancement Stack

Combination: Triptorelin + Recombinant FSH + Estradiol Support

Rationale: After triptorelin suppression, exogenous gonadotropins provide controlled ovarian stimulation while estradiol supplementation maintains endometrial development.

Protocol:

Monitoring: Daily ultrasound from day 20, LH/FSH levels every 48 hours, estradiol levels daily during stimulation phase.

This protocol achieves precise cycle control with pregnancy rates of 35-45% per transfer in women under 35.

Endometriosis Management Stack

Combination: Triptorelin + Norethindrone + Calcium/Vitamin D + Bisphosphonate

Rationale: Complete estrogen suppression treats endometriosis while add-back therapy prevents severe menopausal symptoms and bone loss.

Protocol:

Monitoring: Bone density scan at baseline and 6 months, liver function tests monthly during norethindrone therapy.

This approach maintains endometriosis suppression while preventing >2% bone density loss and reducing hot flash severity by 60-70%.

Prostate Cancer Optimization Stack

Combination: Triptorelin + Antiandrogen + Bone Protection

Rationale: Combined androgen blockade improves cancer control while bone-protective agents prevent fractures during long-term ADT.

Protocol:

Monitoring: PSA monthly for 6 months then every 3 months, bone density annually, fracture risk assessment (FRAX score) every 2 years.

Combined therapy reduces PSA progression risk by 25-30% versus triptorelin alone while maintaining bone density within 5% of baseline.

Safety Deep Dive

Triptorelin's safety profile reflects its potent hormonal effects, with side effects ranging from predictable hormone-related symptoms to rare but serious complications.

Common Side Effects

Hot Flashes: Occur in 80-95% of patients within 2-4 weeks of treatment initiation. Severity peaks at 6-8 weeks, with episodes lasting 2-5 minutes occurring 8-15 times daily. Mechanism involves hypothalamic thermoregulatory dysfunction secondary to estrogen withdrawal.

Decreased Libido: Affects 70-85% of patients, typically developing within 4-6 weeks. Complete loss of sexual interest occurs in 40-50% of cases. Recovery begins 2-6 months after treatment discontinuation but may be incomplete in 15-20% of long-term users.

Mood Changes: Depression or emotional lability affects 45-60% of patients. Symptoms range from mild irritability to severe depression requiring antidepressant therapy. Risk factors include previous mood disorders and concurrent stressors.

Injection Site Reactions: Local pain, swelling, or induration occurs at 15-25% of injection sites with depot formulations. Symptoms typically resolve within 48-72 hours but can persist for up to 2 weeks with deep intramuscular injections.

Bone Density Loss: Accelerated bone loss occurs at 2-4% per year during treatment, compared to normal age-related loss of 0.5-1% annually. Trabecular bone (spine) shows greater loss than cortical bone (hip). Recovery is incomplete, with 10-15% permanent density reduction after 6 months of therapy.

Rare/Theoretical Risks

Pituitary Apoplexy: Fewer than 50 cases reported worldwide, but potentially life-threatening. Risk appears highest in patients with pre-existing pituitary adenomas. Symptoms include sudden severe headache, visual disturbances, and altered consciousness requiring emergency neurosurgical evaluation.

Ovarian Hyperstimulation Syndrome: Paradoxical OHSS can occur when triptorelin is used for ovulation triggering, affecting 1-3% of patients. Severe cases involve ascites, pleural effusion, and thromboembolism. Risk factors include young age, high AMH levels, and previous OHSS history.

Cardiovascular Events: Long-term androgen deprivation increases cardiovascular risk by 15-20%. Mechanisms include adverse lipid changes, insulin resistance, and endothelial dysfunction. Risk is highest in men with pre-existing coronary disease.

Cognitive Impairment: "Chemo-brain" symptoms affect 20-30% of patients during treatment. Deficits include memory problems, difficulty concentrating, and processing speed reduction. Most symptoms resolve within 6-12 months post-treatment, but subtle deficits may persist.

Anaphylaxis: Severe allergic reactions occur in <0.1% of patients but can be fatal. Risk appears higher with repeated depot injections. All patients should be observed for 30 minutes after first injection, with epinephrine readily available.

Contraindications

Absolute Contraindications:

Relative Contraindications:

Special Populations:

Drug Interactions: Triptorelin has minimal cytochrome P450 interactions but can affect the efficacy of hormone-dependent medications. Warfarin dosing may require adjustment due to changes in protein synthesis. Insulin requirements often decrease during treatment due to improved insulin sensitivity.

Compared to Alternatives

Triptorelin competes with several other GnRH analogs and alternative approaches for hormone manipulation, each with distinct advantages and limitations.

Versus Leuprolide: Triptorelin shows superior receptor binding affinity (Kd 0.23 nM vs 0.49 nM) and longer duration of suppression. Head-to-head studies in prostate cancer show equivalent efficacy, but triptorelin causes fewer injection site reactions (12% vs 23%) and has better patient-reported tolerability scores.

Versus Goserelin: Both agents achieve similar suppression rates, but triptorelin's subcutaneous formulation offers easier administration than goserelin's implant system. Triptorelin shows faster onset of suppression (14 vs 21 days) but similar recovery time post-treatment (3-6 months).

Versus Cetrorelix: The GnRH antagonist cetrorelix avoids the flare effect but requires daily injections and costs 30-40% more for equivalent cycle control. Cetrorelix offers immediate suppression but lacks the ovulation-triggering capability that makes triptorelin versatile for different IVF protocols.

Versus hCG: For ovulation triggering, triptorelin provides equivalent oocyte maturation with 60-70% lower OHSS rates. However, hCG better supports luteal phase function and may improve implantation rates in some patient populations. Cost favors hCG significantly ($25 vs $180 per cycle).

Clinical Decision Factors:

What's Coming Next

Triptorelin research continues evolving with new formulations, delivery methods, and applications expanding its therapeutic potential.

Extended-Release Formulations: The TRIPTODUR 6-month formulation completed Phase III trials in 2023, showing equivalent suppression to monthly injections with improved patient compliance (94% vs 78% adherence rates). FDA approval is expected in 2024 for pediatric indications, with adult applications following.

Oral Delivery Systems: Researchers at Endo Pharmaceuticals are developing enteric-coated triptorelin tablets using permeation enhancer technology. Phase I studies show 12-15% bioavailability compared to injection, requiring 10-fold higher doses but offering patient-preferred oral dosing.

Nasal Spray Optimization: FerringVentures is testing a novel nasal delivery system using chitosan nanoparticles that increase mucosal absorption by 300-400%. This technology could enable precise ovulation triggering with improved patient convenience and reduced injection anxiety.

Targeted Cancer Applications: The PRONOUNCE trial (enrolling 2024-2026) will test triptorelin combined with PARP inhibitors in BRCA-positive prostate cancer. Preclinical studies suggest synergistic effects through enhanced DNA repair pathway disruption.

Fertility Preservation: Yale Reproductive Medicine is investigating triptorelin for ovarian protection during chemotherapy. The FERTILE-HOPE study will randomize 500 young cancer patients to triptorelin versus placebo during treatment, measuring post-chemotherapy ovarian reserve and pregnancy rates.

Endometriosis Innovation: Researchers are developing selective GnRH receptor modulators (SGRMs) that provide endometriosis suppression without complete estrogen elimination. KLH-2109, entering Phase II trials in 2024, aims to maintain bone density while treating endometriosis symptoms.

Alzheimer's Prevention: Emerging research suggests GnRH analogs might protect against tau protein aggregation. The MIND-GnRH study will treat 200 postmenopausal women at high Alzheimer's risk with triptorelin, measuring cognitive function and brain imaging changes over 2 years.

Pediatric Applications: Beyond precocious puberty, triptorelin is being studied for gender dysphoria treatment in adolescents. The controversial GENDER-PAUSE trial will assess reversibility and long-term effects of puberty suppression, with results expected in 2026.

Personalized Dosing: Artificial intelligence algorithms are being developed to predict optimal triptorelin dosing based on genetic polymorphisms in GnRH receptor and metabolizing enzyme genes. The PRECISION-GnRH platform could reduce side effects by 25-35% through individualized therapy.

Combination Therapies: Novel combinations with immune checkpoint inhibitors are entering clinical trials for hormone-sensitive cancers. The hypothesis suggests that androgen deprivation enhances T-cell infiltration and PD-1 inhibitor efficacy in prostate cancer.

Unanswered Questions:

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

Key Takeaways

• Triptorelin is a synthetic GnRH agonist that provides precise control over reproductive hormones through initial stimulation followed by complete suppression

• Clinical applications span fertility, oncology, and pediatrics, with proven efficacy in IVF protocols, endometriosis treatment, prostate cancer management, and precocious puberty intervention

• The "flare-then-suppression" pattern makes triptorelin uniquely versatile — the initial hormone surge triggers ovulation in IVF while sustained treatment achieves medical castration for hormone-dependent conditions

• Dosing varies dramatically by indication, from 0.1mg single doses for ovulation triggering to 22.5mg quarterly injections for prostate cancer, requiring careful protocol selection

• Side effects are primarily hormone-related, including hot flashes (80-95% incidence), decreased libido (70-85%), and accelerated bone loss (2-4% annually during treatment)

• Strategic combinations enhance outcomes — IVF protocols combine with gonadotropins and estradiol, endometriosis treatment adds norethindrone and bone protection, prostate cancer therapy includes antiandrogens and denosumab

• Triptorelin offers advantages over alternatives including superior OHSS prevention versus hCG, better tolerability than leuprolide, and ovulation-triggering capability unavailable with GnRH antagonists

• Safety requires careful monitoring with bone density scans, cardiovascular risk assessment, and psychological evaluation, particularly during long-term treatment

• Future developments include extended-release formulations, oral delivery systems, and novel applications in cancer prevention and neurological disorders

• Patient selection and protocol optimization remain critical for maximizing efficacy while minimizing adverse effects across triptorelin's diverse clinical applications

Related Articles on BuyPeptidesOnline.com

FAQ

Q: How quickly does triptorelin work for ovulation triggering?

A: Triptorelin triggers LH surge within 2-4 hours and ovulation occurs 32-38 hours post-injection, making precise timing critical for IVF egg retrieval scheduling.

Q: Can triptorelin be used instead of hCG for ovulation triggering?

A: Yes, triptorelin provides equivalent oocyte maturation with 60-70% lower OHSS risk, making it preferred for high-responder IVF patients with >15 follicles.

Q: How long does it take to recover fertility after triptorelin treatment?

A: Ovarian function typically returns within 2-6 months after stopping treatment, but recovery may be delayed in women over 35 or those treated for >6 months.

Q: What's the difference between daily and depot triptorelin formulations?

A: Daily injections allow precise control and rapid reversibility, while depot formulations provide sustained suppression for 1-6 months with improved compliance but delayed recovery.

Q: Can triptorelin cause permanent infertility?

A: No documented cases of permanent infertility exist with standard treatment durations, though prolonged use (>2 years) may delay recovery in older patients.

Q: Is bone loss from triptorelin reversible?

A: Partial recovery occurs within 12-24 months post-treatment, but 10-15% of bone density loss may be permanent, especially with treatment >6 months.

Q: Can triptorelin be used during breastfeeding?

A: No, triptorelin is contraindicated during breastfeeding as it suppresses prolactin and can reduce milk production while potentially affecting infant development.

Q: What should I do if I miss a depot injection?

A: Contact your healthcare provider immediately as hormone suppression may be lost within 2-4 weeks, potentially requiring restart of treatment protocols.

Q: Can men use triptorelin for testosterone suppression?

A: Yes, triptorelin achieves medical castration (testosterone <50 ng/dL) in 97% of men within 28 days, commonly used for prostate cancer treatment.

Q: Are there any natural alternatives to triptorelin?

A: No natural compounds provide equivalent GnRH receptor modulation, though lifestyle modifications and certain herbs may influence reproductive hormones less dramatically.